[1] |
Mejía-León ME,Barca AM.Diet,microbiota and immune system in type 1 diabetes development and evolution[J].Nutrients,2015,7(11):9171-9184.
|
[2] |
Campbell-Thompson M,Fu A,Kaddis JS,et al.Insulitis and β-cell mass in the natural history of type 1 diabetes[J].Diabetes,2016,65(3):719-731.
|
[3] |
Lu SP,Jin L,Wu J.Clinical development of type 1 diabetes vaccine[J].J China Pharm Univ(中国药科大学学报),2014,45(6):625-631.
|
[4] |
Cilião HL,Ribeiro DL,Camargo-Godoy RB,et al.Cytotoxic and genotoxic effects of high concentrations of the immunosuppressive drugs cyclosporine and tacrolimus in MRC-5 cells[J].Exp Toxicol Pathol,2015,67(2):179-187.
|
[5] |
Larsson HE,Lernmark Å.Vaccination against type 1 diabetes[J].J Intern Med,2011,269(6):626-635.
|
[6] |
Brown K,Godovannyi A,Ma C,et al.Prolonged antibiotic treatment induces a diabetogenic intestinal microbiome that accelerates diabetes in NOD mice[J].Isme Journal,2016,10(2):321-332.
|
[7] |
Tun HM,Konya T,Takaro TK,et al.Exposure to household furry pets influences the gut microbiota of infant at 3-4 months following various birth scenarios[J].Microbiome,2017,5(1):40.
|
[8] |
Livanos AE,Greiner TU,Vangay P,et al.Antibiotic-mediated gut microbiome perturbation accelerates development of type 1 diabetes in mice[J].Nat Microbiol,2016,1(11):16140.
|
[9] |
Knip M,Honkanen J.Modulation of type 1 diabetes risk by the intestinal microbiome[J].Curr Diab Rep,2017,17(11):105.
|
[10] |
Op de Beeck A,Eizirik DL.Viral infections in type 1 diabetes mellitus-why the β cells[J]?Nat Rev Endocrinol,2016,12(5):263-273.
|
[11] |
Kostic, Aleksandar, Gevers, et al. The dynamics of the human infant gut microbiome in development and in progression toward type 1 diabetes[J].Cell Host Microb,2015,17(2):260-273.
|
[12] |
Johnson AT.The hygiene hypothesis[J].IEEE Pulse,2016,7(1):50-51.
|
[13] |
Bach JF.The hygiene hypothesis in autoimmunity:the role of pathogens and commensals[J] Nat Rev Immunol,2018,18(2):105-120.
|
[14] |
Dénes B,Fodor I,Langridge WH.Persistent suppression of type 1 diabetes by a multicomponent vaccine containing a cholera toxin B subunit-autoantigen fusion protein and complete Freund′s adjuvant[J].Clin Dev Immunol,2013,2013(12):578786.
|
[15] |
Mori Y,Kodaka T,Kato T,et al.Critical role of IFN-γ in CFA-mediated protection of NOD mice from diabetes development[J].Int Immunol,2009,21(11):1291-1299.
|
[16] |
Lee IF,Qin H,Trudeau J,et al.Regulation of autoimmune diabetes by complete Freund′s adjuvant is mediated by NK cells[J].J Immunol,2004,172(2):937-942.
|
[17] |
Petrovsky N.Immunomodulation with microbial vaccines to prevent type 1 diabetes mellitus [J].Nat Rev Endocrinol,2010,6(3):131-138.
|
[18] |
Silva DG,Charlton B,Cowden W,et al.Prevention of autoimmune diabetes through immunostimulation with Q fever complement-fixing antigen[J].Ann N Y Acad Sci,2003,1005(1):423-430.
|
[19] |
White M,Webster G,Leonard F,et al.Innate IFN-γ ameliorates experimental autoimmune encephalomyelitis and promotes myeloid expansion and PDL-1 expression[J].Sci Rep,2018,8(1):259.
|
[20] |
Luca S,Mihaescu T.History of BCG vaccine[J].Maedica,2013,8(1):53.
|
[21] |
Iqbal NT,Hussain R.Non-specific immunity of BCG vaccine:a perspective of BCG immunotherapy[J].Trials Vaccinol,2014,3(C):143-149.
|
[22] |
Surendar J,Indulekha K,Hoerauf A,et al.Immunomodulation by helminths:similar impact on type 1 and type 2 diabetes[J]?Parasite Immunol,2017,39(5):e12401.
|
[23] |
Finlay CM,Stefanska AM,Walsh KP,et al.Helminth products protect against autoimmunity via innate type 2 cytokines IL-5 and IL-33,which promote eosinophilia[J].J Immunol,2016,196(2):703-714.
|
[24] |
Hernandez JL, Leung G, McKay DM. Cestode regulation of inflammation and inflammatory diseases[J].Int J Parasitol,2013,43(3/4):233-243.
|
[25] |
Fleming JO,Weinstock JV.Clinical trials of helminth therapy in autoimmune diseases:rationale and findings[J].Parasite Immunol,2015,37(6):277-292.
|
[26] |
Tracy S,Drescher KM,Chapman NM,et al.Toward testing the hypothesis that group B coxsackieviruses(CVB)trigger insulin-dependent diabetes:inoculating nonobese diabetic mice with CVB markedly lowers diabetes incidence[J].J Virol,2002,76(23):12097-12111.
|
[27] |
Filippi CM,Estes EA,Oldham JE,et al.Immunoregulatory mechanisms triggered by viral infections protect from type 1 diabetes in mice[J].J Clin Invest,2009,119(6):1515-1523.
|
[28] |
Mccall KD,Thuma JR,Courreges MC,et al.Toll-like receptor 3 is critical for coxsackievirus B4-induced type 1 diabetes in female NOD mice[J].Endocrinology,2015,156(2):453-461.
|
[29] |
Bignon A, Watt AP,Linterman MA.Escherichia coli heat-labile enterotoxin B limits T cells activation by promoting immature dendritic cells and enhancing regulatory T cell function[J].Front Immunol,2017,8:560.
|
[30] |
Ola TO,Williams NA.Protection of non-obese diabetic mice from autoimmune diabetes by Escherichia coli heat-labile enterotoxin B subunit[J].Immunology,2006,117(2):262-270.
|
[31] |
Xuan J,Wang L,Yin H,et al.The cost-effectiveness of OM-85 in managing respiratory tract infections in China[J].J Med Econ,2015,18(3):167-172.
|
[32] |
Alyanakian MA, Grela F, Aumeunier A, et al. Transforming growth factor-beta and natural killer T-cells are involved in the protective effect of a bacterial extract on type 1 diabetes[J].Diabetes,2006,55(1):179-185.
|
[33] |
Hartmann B,Bellmann K,Ghiea I,et al.Oral insulin for diabetes prevention in NOD mice:potentiation by enhancing Th2 cytokine expression in the gut through bacterial adjuvant[J].Diabetologia,1997,40(8):902-909.
|
[34] |
Aude A, Françoise G, Abdulraouf R, et al. Systemic Toll-like receptor stimulation suppresses experimental allergic asthma and autoimmune diabetes in NOD mice[J].Plos One,2010,5(7):e11484.
|
[35] |
Caramalho I,Rodrigues-Duarte L,Perez A,et al.Regulatory T cells contribute to diabetes protection in lipopolysaccharide-treated non-obese diabetic mice[J].Scand J Immunol,2011,74(6):585-595.
|
[36] |
Wang J,Cao H,Wang H,et al.Multiple mechanisms involved in diabetes protection by lipopolysaccharide in non-obese diabetic mice[J].Toxicol Appl Pharmacol,2015,285(3):149-158.
|
[37] |
Gianchecchi E, Fierabracci A. On the pathogenesis of insulin-dependent diabetes mellitus:the role of microbiota[J].Immunol Res,2017,65(1):242-256.
|
[38] |
Shintani S,Satoh J,Seino H,et al.Mechanism of action of a streptococcal preparation(OK-432)in prevention of autoimmune diabetes in NOD mice.Suppression of generation of effector cells for pancreatic B cell destruction[J].J Immunol,1990,144(1):136-141.
|
[39] |
Burrows MP,Volchkov P,Kobayashi KS,et al.Microbiota regulates type 1 diabetes through Toll-like receptors[J].Proc Natl Acad Sci U S A,2015,112(32):9973-9977.
|
[40] |
Quintana FJ,Rotem A,Carmi P,et al.Vaccination with empty plasmid DNA or CpG oligonucleotide inhibits diabetes in nonobese diabetic mice:modulation of spontaneous 60-kDa heat shock protein autoimmunity[J].J Immunol,2000,165(11):6148-6155.
|
[41] |
Lee BJ,Kim SK,Kim MK,et al.Limited effect of CpG ODN in preventing type 1 diabetes in NOD mice[J].Yonsei Med J,2005,46(3):341-346.
|
[42] |
Husseiny MI,Rawson J,Kaye A,et al.An oral vaccine for type 1 diabetes based on live attenuated Salmonella[J].Vaccine,2014,32(20):2300-2307.
|
[43] |
Duan FF, Liu JH, March JC. Engineered commensal bacteria reprogram intestinal cells into glucose-responsive insulin-secreting cells for the treatment of diabetes[J].Diabetes,2015,64(5):1794-1803.
|
[44] |
Robert S,Gysemans C,Takiishi T,et al.Oral delivery of glutamic acid decarboxylase(GAD)-65 and IL10 by Lactococcus lactis reverses diabetes in recent-onset NOD mice[J].Diabetes,2014,63(8):2876-2887.
|
[45] |
Saxena A, Yagita H, Donner TW, et al. Expansion of FasL-expressing CD5+ B cells in type 1 diabetes patients[J].Front Immunol,2017,8(3):402.
|
[46] |
Osińska I,Popko K,Demkow U.Perforin:an important player in immune response[J].Cent Eur J Immunol,2014,39(1):109-115.
|
[47] |
Klocke K,Sakaguchi S,Holmdahl R,et al.Induction of autoimmune disease by deletion of CTLA-4 in mice in adulthood[J].Proc Natl Acad Sci U S A,2016,113(17):E2383-E2392.
|
[48] |
Bednar KJ, Tsukamoto H, Kachapati K, et al. Reversal of new-onset type 1 diabetes with an agonistic TLR4/MD-2 monoclonal antibody[J].Diabetes,2015,64(10):3614-3626.
|
[49] |
Mellati M,Eaton KD,Brooks-Worrell BM,et al.Anti-PD-1 and Anti-PDL-1 monoclonal antibodies causing type 1 diabetes[J].Diabetes Care,2015,38(9):e137.
|